Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan-Ruide Li

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 26, 2026
Toward scalable helper T cells from iPSCsYan-Ruide Li
Cell Reports. Medicine|November 19, 2025
From bench to body: In vivo CAR engineering in the clinicYan-Ruide Li, Lili Yang
Molecular Biology Reports|December 29, 2017
Upf proteins: highly conserved factors involved in nonsense mRNA mediated decayPuneet Gupta, Yan-Ruide Li
Molecular Biology Reports|December 17, 2018
Immune aspects of the bi-directional neuroimmune facilitator TRPV1Yan-Ruide Li, Puneet Gupta
Frontiers in Oncology|January 26, 2026
Frontiers of cytokine engineering in CAR cell therapy for cancerYinghan Wu, Yan-Ruide Li
Trends in Pharmacological Sciences|November 26, 2025
Autologous, allogeneic, in vivo CAR for autoimmune diseasesYan-Ruide Li, Lili Yang
Current Pharmaceutical Biotechnology|February 4, 2024
Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor MicroenvironmentYiqing Wang, Yan-Ruide Li
Bioengineering (Basel, Switzerland)|January 24, 2025
iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer TreatmentJiepu Zong, Yan-Ruide Li
STAR Protocols|January 14, 2026
Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinomaYan-Ruide Li, Lili Yang
Gene|October 20, 2015
Myosin superfamily: The multi-functional and irreplaceable factors in spermatogenesis and testicular tumorsYan-Ruide Li, Wan-Xi Yang
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 26, 2026
Toward scalable helper T cells from iPSCsYan-Ruide Li
Cell Reports. Medicine|November 19, 2025
From bench to body: In vivo CAR engineering in the clinicYan-Ruide Li, Lili Yang
Molecular Biology Reports|December 29, 2017
Upf proteins: highly conserved factors involved in nonsense mRNA mediated decayPuneet Gupta, Yan-Ruide Li
Molecular Biology Reports|December 17, 2018
Immune aspects of the bi-directional neuroimmune facilitator TRPV1Yan-Ruide Li, Puneet Gupta
Frontiers in Oncology|January 26, 2026
Frontiers of cytokine engineering in CAR cell therapy for cancerYinghan Wu, Yan-Ruide Li
Trends in Pharmacological Sciences|November 26, 2025
Autologous, allogeneic, in vivo CAR for autoimmune diseasesYan-Ruide Li, Lili Yang
Current Pharmaceutical Biotechnology|February 4, 2024
Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor MicroenvironmentYiqing Wang, Yan-Ruide Li
Bioengineering (Basel, Switzerland)|January 24, 2025
iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer TreatmentJiepu Zong, Yan-Ruide Li
STAR Protocols|January 14, 2026
Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinomaYan-Ruide Li, Lili Yang
Gene|October 20, 2015
Myosin superfamily: The multi-functional and irreplaceable factors in spermatogenesis and testicular tumorsYan-Ruide Li, Wan-Xi Yang
Pageof 10